Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma

Size: px
Start display at page:

Download "Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma"

Transcription

1 Media Release Basel, 12 January 2017 Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma Administration time significantly reduced with subcutaneous formulation Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has approved a new subcutaneous formulation of MabThera (rituximab) for the treatment of two types of non-hodgkin lymphoma follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). We are pleased that the time-saving subcutaneous formulation of MabThera has now also been approved in Switzerland for the treatment of common types of non-hodgkin lymphoma, said Professor Anja-Alexandra Dünne, Country Medical Director, Roche Pharma (Switzerland) Ltd. Because the treatment is simpler and faster to administer, the burden on the patient is considerably reduced. With the new formulation, the time required for the administration of MabThera can be reduced to five to seven minutes, compared to the roughly 2.5-hour infusion time for intravenous MabThera. In the extensive study 1, subcutaneous administration was preferred by 80% of patients who had received both intravenous and subcutaneous MabThera in the course of treatment. The latter was felt to be more comfortable during administration and had a lower psychological impact. About the pivotal studies The Swiss approval was largely based on data from the pivotal SABRINA study 2 5, which demonstrated that subcutaneous MabThera is non-inferior to the intravenous formulation with regard to efficacy and safety in the FL indication. In addition, for the DLBCL indication, the MABEASE study 6 showed that similar safety and efficacy outcomes are achieved in patients switching from intravenous to subcutaneous administration. F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Group Communications Roche Group Media Relations Tel /5

2 About MabThera MabThera is a therapeutic monoclonal antibody that binds to a particular protein the CD20 antigen on the surface of normal and malignant B-cells. It then recruits the body s natural defences to attack and kill the marked B-cells. Stem cells (B-cell progenitors) in bone marrow lack the CD20 antigen, allowing healthy B- cells to regenerate after treatment and return to normal levels within several months. Over the past 20 years, MabThera has been shown to be effective in a wide variety of indications. MabThera was first approved in Switzerland in 1997 for induction therapy in patients with relapsed FL. There followed a number of additional approvals for non-hodgkin lymphoma indications previously untreated FL and DLBCL and for chronic lymphocytic leukemia (CLL). In addition, MabThera has been approved in Switzerland for the treatment of certain non-oncology diseases rheumatoid arthritis (RA) and ANCA-associated vasculitis (AAV). About subcutaneous MabThera The subcutaneous form of MabThera is a ready-to-use liquid formulation that is administered as a 1400 mg/11.7 ml fixed dose. This simplifies healthcare procedures by removing the need for reconstitution or dose calculation according to individual body weight. The subcutaneous formulation of MabThera uses a recombinant human hyaluronidase technology that produces temporary local degradation of hyaluronan in subcutaneous tissue. This leads to a temporary increase in the subcutaneous space, permitting pain-free administration of larger volumes of liquid into the abdominal wall. This enables the 11.7 ml volume of the subcutaneous formulation of MabThera to be dispersed and absorbed over a greater area in approximately 5 minutes. The subcutaneous tissue returns to its original state about 24 hours after subcutaneous administration. 2/5

3 About non-hodgkin lymphoma 7,8 There are two main types of lymphoma: Hodgkin lymphoma and non-hodgkin lymphoma (NHL). NHL represents approximately 85% of all lymphomas diagnosed. Lymphomas are a cancer of the lymphatic system (composed of lymph vessels, lymph nodes and organs) which helps to keep the bodily fluid levels balanced and to defend the body against invasion by disease. Lymphoma develops when white blood cells (usually B-lymphocytes) in the lymph fluid become cancerous and begin to multiply and collect in the lymph nodes or lymphatic tissues such as the spleen. Some of these cells are released into the bloodstream and spread around the body, interfering with the body s production of healthy blood cells.. Follicular lymphoma (FL) is the most common type of indolent NHL, accounting for around 25% of all cases of NHL. As the progression of FL is usually slow and painless, the majority of patients are diagnosed at a late stage. Like most other lymphomas, FL occurs more frequently in older patients. Diffuse large B-cell lymphoma (DLBCL) is the most common type of malignant lymphoma in the Western world, accounting for approximately 30% of all cases of NHL. It has an aggressive course, with a median survival of less than a year in untreated patients. Typical of DLBCL are fast-growing tumour masses which can occur almost anywhere in the body and, as well as pain, can cause various symptoms such as fever, weight loss and night sweats. DLBCL is a potentially curable lymphoma; indeed, more than 50% of patients can be permanently cured. DLBCL most commonly affects older patients, with the median age at the time of diagnosis being 70 years. About Roche in haematology For more than 20 years, Roche has been developing medicines that redefine treatment in haematology. In addition to MabThera and Gazyvaro, Roche s pipeline includes further potential haematology medicines. 3/5

4 About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people s lives. Roche is the world s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. Roche Group Media Relations Tel / roche.mediarelations@roche.com - Nicolas Dunant (Head) - Ulrike Engels-Lange - Anja von Treskow 4/5

5 References: 1. Rummel M., Min Kim T., Plenteda C. et al. Prefmab: final analysis of patient preference for subcutaneous versus intravenous rituximab in previously untreated CD20+ diffuse large B-cell lymphoma and follicular lymphoma. [Poster 3972] American Society of Hematology (Orlando, Florida, USA) Davies A., Merli F., Mihaljevic B. et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncology 2014;15: Davies A., Merli F., Mihaljevic B. et al. Subcutaneous rituximab and chemotherapy achieves similar overall response rates to intravenous rituximab in first-line follicular lymphoma: efficacy and safety results of the phase III SABRINA study. Abstract. European Hematology Association (Milan, Italy) Davies A., Mihaljevic B., Mercadal S. et al. Comparison of subcutaneous and intravenous rituximab in the maintenance setting: updated safety results of the phase III SABRINA study in patients with follicular lymphoma. Abstract. European Hematology Association (Vienna, Austria) Davies A., Mihaljevic B., Mercadal S. et al. Longer term efficacy and safety of subcutaneous compared with intravenous rituximab: updated results of the phase 3 SABRINA study. Abstract. American Society of Hematology (San Diego, USA) Lugtenburg P. et al. Subcutaneous versus intravenous rituximab in combination with CHOP for previously untreated diffuse large B-cell lymphoma: efficacy and safety results from the phase IIIB MABEASE study. Abstract. European Hematology Association (Vienna, Austria) Hitz F, Ketterer N, Lohri A, Mey U, Pederiva S, Renner C, Taverna C, Hartmann A, Yeow K, Bodis S, Zucca E. Diagnosis and treatment of follicular lymphoma. Swiss Med Wkly Aug 4;141:w doi: /smw Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, Meier O, Yeow K, Renner C. Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Med Wkly Jan 30;142:w doi: /smw /5

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Media Release Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes,

More information

Investor Update. Downloads. Services PDF. Basel, 23 June 2017

Investor Update. Downloads. Services PDF. Basel, 23 June 2017 Investor Update Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes,

More information

Roche s GAZYVARO approved in Switzerland for people with previously untreated follicular lymphoma which are in need of systemic treatment

Roche s GAZYVARO approved in Switzerland for people with previously untreated follicular lymphoma which are in need of systemic treatment Media Release Basel, 25 July 2017 Roche s GAZYVARO approved in Switzerland for people with previously untreated follicular lymphoma which are in need of systemic treatment Approval is based on phase III

More information

CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma

CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma Media Release Basel, 29 April 2016 CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma In the pivotal study, treatment with Gazyvaro plus bendamustine

More information

Media Release. Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 22 September 2017

Media Release. Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 22 September 2017 Media Release Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which

More information

Media Release. CHMP recommends EU approval of Roche s Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 21 July 2017

Media Release. CHMP recommends EU approval of Roche s Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 21 July 2017 Media Release Basel, 21 July 2017 CHMP recommends EU approval of Roche s Gazyvaro for people with previously untreated advanced follicular lymphoma Pivotal GALLIUM study demonstrated that Gazyvaro-based

More information

Media Release. Basel, 5 December 2016

Media Release. Basel, 5 December 2016 Media Release Basel, 5 December 2016 Roche s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan

More information

Media Release. Basel, 10 December 2017

Media Release. Basel, 10 December 2017 Media Release Basel, 10 December 2017 Phase II data showed Roche s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone

More information

Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia

Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia Media Release Basel, 12 April 2016 Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia Venclexta is designed to help

More information

Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma

Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Media Release Basel, 23 June 2017 Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Longer follow-up showed

More information

Media Release. Basel, 12 December 2017

Media Release. Basel, 12 December 2017 Media Release Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of

More information

Media Release. Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia

Media Release. Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Media Release Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Approval is based on randomised phase III MURANO study showing that

More information

Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer

Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary

More information

Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting

Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Media Release Basel, 5 November 2015 Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Gazyva/Gazyvaro (obinutuzumab) and investigational

More information

Media Release. FDA grants Priority Review for Roche s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer

Media Release. FDA grants Priority Review for Roche s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Media Release Basel, 29 September 2017 FDA grants Priority Review for Roche s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced

More information

Media Release. Basel, 7 May 2018

Media Release. Basel, 7 May 2018 Media Release Basel, 7 May 2018 FDA grants priority review to Roche s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche

More information

Media Release. Basel, 26 March 2018

Media Release. Basel, 26 March 2018 Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live

More information

Media Release. Basel, 18 February 2017

Media Release. Basel, 18 February 2017 Media Release Basel, 18 February 2017 Phase II study supports potential for Roche s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma

More information

Media Release. Basel, 20 March 2018

Media Release. Basel, 20 March 2018 Media Release Basel, 20 March 2018 Phase III IMpower131 study showed Roche s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the

More information

Accelerated approval of Perjeta for neoadjuvant use also converted to full approval

Accelerated approval of Perjeta for neoadjuvant use also converted to full approval Media Release Basel, 21 December 2017 FDA approves Roche s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer Accelerated approval of Perjeta for neoadjuvant use also converted

More information

Media Release. Basel, 07 December 2017

Media Release. Basel, 07 December 2017 Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent

More information

Media Release. Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress

Media Release. Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress Media Release Basel, 08 September 2017 Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for

More information

Media Release. Basel, 7 November 2013

Media Release. Basel, 7 November 2013 Media Release Basel, November 2013 Roche s Gazyva helped people with one of the most common forms of blood cancer live significantly longer without their disease worsening compared to MabThera/Rituxan

More information

Media Release. Basel, 17 May 2018

Media Release. Basel, 17 May 2018 Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly

More information

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase

More information

Media Release. Basel, 10 November 2017

Media Release. Basel, 10 November 2017 Media Release Basel, 10 November 2017 Roche s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis If approved, OCREVUS

More information

FDA approves Roche s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer

FDA approves Roche s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Media Release Basel, 07 November 2017 FDA approves Roche s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Approval based on phase III results that showed Alecensa

More information

European Commission approves Roche s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer

European Commission approves Roche s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Media Release Basel, 21 December 2017 European Commission approves Roche s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Alecensa provides a new treatment option for people with

More information

Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer

Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)

More information

Roche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis

Roche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis Media Release Basel, 28 September 2017 Roche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis OCREVUS is the first and only approved treatment

More information

Media Release. Basel, 17 May 2018

Media Release. Basel, 17 May 2018 Media Release Basel, 17 May 2018 Follow-up phase III data showed Roche s Alecensa helped people with ALKpositive metastatic non-small cell lung cancer live a median of almost three years without their

More information

Media Release. Basel, 21 July 2017

Media Release. Basel, 21 July 2017 Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential

More information

Media Release. Basel, 6 th February 2018

Media Release. Basel, 6 th February 2018 Media Release Basel, 6 th February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain

More information

Investor Update. Downloads. Services PDF. Basel, 15 May 2018

Investor Update. Downloads. Services PDF. Basel, 15 May 2018 Investor Update Basel, 15 May 2018 FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pjia), a rare form of juvenile arthritis Roche (SIX: RO,

More information

Roche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics.

Roche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics. Media Release PRIME designation granted by European Medicines Agency for Roche s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the

More information

Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Investor Update Basel, 20 November 2017 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening

More information

About NP28673 About NP28761

About NP28673 About NP28761 Media Release Basel, 14 May 2015 Roche s investigational medicine alectinib shrank tumours in nearly half of people with specific type of lung cancer Alectinib showed response rates of up to 69% in the

More information

Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer

Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer Media Release Basel, 31 July, 2015 Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer The approval is based on the benefit seen with the Perjeta regimen

More information

Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine

Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine Media Release Basel 21 December 2016 Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational

More information

Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer

Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer Media Release Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer The VENTANA MMR IHC Panel 1 helps differentiate between sporadic colorectal cancer

More information

Investor Update. Downloads. Services PDF. Basel, 17 July 2017

Investor Update. Downloads. Services PDF. Basel, 17 July 2017 Investor Update Basel, 17 July 2017 Roche s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and

More information

FDA approves Roche s Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema

FDA approves Roche s Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema Media Release Basel, 9 February 2015 FDA approves Roche s Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema First eye medicine approved for treatment

More information

Investor Update. Basel, 23 April 2018

Investor Update. Basel, 23 April 2018 Investor Update Basel, 23 April 2018 New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis Four years of

More information

Investor Update. Basel, 10 May 2018

Investor Update. Basel, 10 May 2018 Investor Update Basel, 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal

More information

Media Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Media Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Media Release Basel, 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 19 Roche medicines are included in

More information

FDA grants Roche s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer

FDA grants Roche s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer Investor Update Basel, 3 August 2017 FDA grants Roche s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the

More information

Media Release. Basel, 5 June 2017

Media Release. Basel, 5 June 2017 Media Release Basel, 5 June 2017 APHINITY study shows Roche s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2- positive early breast cancer

More information

New STAIRWAY study data shows potential for extended durability with Roche s faricimab in neovascular age-related macular degeneration (namd)

New STAIRWAY study data shows potential for extended durability with Roche s faricimab in neovascular age-related macular degeneration (namd) Media Release New STAIRWAY study data shows potential for extended durability with Roche s faricimab in neovascular age-related macular degeneration (namd) Faricimab the first bispecific antibody designed

More information

Media Release. China National Drug Administration grants rapid approval of Roche s Alecensa (alectinib) as a treatment for ALK-positive lung cancer

Media Release. China National Drug Administration grants rapid approval of Roche s Alecensa (alectinib) as a treatment for ALK-positive lung cancer Media Release China National Drug Administration grants rapid approval of Roche s Alecensa (alectinib) as a treatment for ALK-positive lung cancer Approval follows priority review of Alecensa in China,

More information

Investor Update. Basel, 24 January 2017

Investor Update. Basel, 24 January 2017 Investor Update Basel, 24 January 2017 FDA grants priority review for Roche s Actemra/RoActemra (tocilizumab) supplemental biologics license application for giant cell arteritis, a form of vasculitis Roche

More information

Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer

Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer Media Release Basel, 1 June 2013 Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer Roche (SIX: RO, ROG; OTCQX:

More information

Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer

Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer Media Release Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides

More information

Follow Roche on Twitter and keep up to date with WCLC 2018 congress news and updates by using the hashtag #WCLC2018.

Follow Roche on Twitter and keep up to date with WCLC 2018 congress news and updates by using the hashtag #WCLC2018. Media Release Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) New and updated pivotal data from the lung programme, including overall

More information

Media Release. Basel, 21 May 2018

Media Release. Basel, 21 May 2018 Media Release Basel, 21 May 2018 Roche s Hemlibra reduced treated by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors In a subset of patients

More information

Media Release. Basel, 29 September 2014

Media Release. Basel, 29 September 2014 Media Release Basel, 29 September 2014 Roche s investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone Cobimetinib

More information

Media Release. FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer

Media Release. FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer Media Release Basel, 1 October 2013 FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer The Perjeta regimen is the first treatment

More information

NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)

NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973) NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) 467-6800 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen (973) 235-3655 Biogen Idec Contacts: Media: Christina Chan (781) 464-3260

More information

Media Release. Basel, 17 November 2012

Media Release. Basel, 17 November 2012 Media Release Basel, 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy

More information

Media Release. Basel, 3 June 2012

Media Release. Basel, 3 June 2012 Media Release Basel, 3 June 2012 Roche s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III

More information

Investor Update. Basel, 21 October 2018

Investor Update. Basel, 21 October 2018 Investor Update Basel, 21 October 2018 Updated data showed that Roche's Tecentriq in combination with Avastin shrank tumours in people with unresectable or advanced hepatocellular carcinoma (HCC) Data

More information

Media Release. Basel 12 January 2018

Media Release. Basel 12 January 2018 Media Release Basel 12 January 2018 Roche s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved

More information

Roche to provide HIV diagnostic solutions to Global Fund. Framework agreement with Global Fund strengthens access to HIV diagnostics

Roche to provide HIV diagnostic solutions to Global Fund. Framework agreement with Global Fund strengthens access to HIV diagnostics Media Release June 18, 2015 Roche to provide HIV diagnostic solutions to Global Fund Framework agreement with Global Fund strengthens access to HIV diagnostics Roche (SIX: RO, ROG; OTCQX: RHHBY) announced

More information

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Media Release Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal combination

More information

Media Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011

Media Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011 Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived

More information

Media Release. Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO. Basel, 11 May 2015

Media Release. Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO. Basel, 11 May 2015 Media Release Basel, 11 May 2015 Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO Roche medicines to be featured in more than 275 abstracts during ASCO 2015 New pivotal

More information

Investor Update. Services. Investor Relations team Send . Basel, 24 May Subscribe to Roche news

Investor Update. Services. Investor Relations team Send  . Basel, 24 May Subscribe to Roche news Investor Update Basel, 24 May 2017 New data at ATS add to the body of evidence for Roche s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet

More information

GENENTECH AND BIOGEN IDEC RECEIVE A COMPLETE RESPONSE FROM FDA FOR EARLIER USE OF RITUXAN FOR RHEUMATOID ARTHRITIS

GENENTECH AND BIOGEN IDEC RECEIVE A COMPLETE RESPONSE FROM FDA FOR EARLIER USE OF RITUXAN FOR RHEUMATOID ARTHRITIS NEWS RELEASE Genentech Contacts: Media / Advocacy: Megan Pace (650) 467-7334 Investor: Susan Morris (650) 225-6523 Karl Mahler 011 41 61 68785 03 Biogen Idec Contacts: Media: Amy Reilly (617) 914-6524

More information

Rituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description

Rituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description

More information

FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema

FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema Investor Update Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First Major Treatment Advance in More Than 25 Years for Sight-Threatening Condition

More information

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Investor Update Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal

More information

Combination of Roche medicines Cotellic and Zelboraf approved in Switzerland for the treatment of patients with advanced melanoma

Combination of Roche medicines Cotellic and Zelboraf approved in Switzerland for the treatment of patients with advanced melanoma Media Release Basel, 27 August 2015 Combination of Roche medicines Cotellic and Zelboraf approved in Switzerland for the treatment of patients with advanced melanoma New treatment option for patients with

More information

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells

More information

Investor Update. Basel, 14 April 2018

Investor Update. Basel, 14 April 2018 Investor Update Basel, 14 April 2018 Roche to present data on (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate

More information

Mathias J Rummel, MD, PhD

Mathias J Rummel, MD, PhD I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track

More information

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are

More information

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability

More information

RITUXAN (rituximab and hyaluronidase human)

RITUXAN (rituximab and hyaluronidase human) Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria

More information

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England

More information

Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma

Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma 1 st Appraisal Committee meeting Background and Clinical Effectiveness Committee A Lead team John Watkins

More information

Rituximab in the Treatment of NHL:

Rituximab in the Treatment of NHL: New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,

More information

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing

More information

Roche reports strong sales growth in the first nine months of Sales CHF millions As % of sales % change

Roche reports strong sales growth in the first nine months of Sales CHF millions As % of sales % change Investor Update Basel, 19 October 2017 Roche reports strong sales growth in the first nine months of 2017 Group sales increase 5% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division

More information

LYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital

LYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital LYMPHOMA DIAGNOSIS and PROGNOSIS LC Lim Dept of Hematology Singapore General Hospital OUTLINE Accurate diagnosis Define subtype : WHO classification Staging : Defines extent of involvement Prognosis Determining

More information

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Document Number: IC-0322 Last Review Date: 02/06/2018 Date of Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011,

More information

Rituximab for the first-line treatment of stage III-IV follicular lymphoma

Rituximab for the first-line treatment of stage III-IV follicular lymphoma Rituximab for the first-line treatment of stage III-IV (review of guidance 110) Issued: January 2012 guidance.nice.org.uk/ta243 NICE has accredited the process used by the Centre for Health Technology

More information

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies

More information

B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma

B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is

More information

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells

More information

Media Release. Roche committed to innovation and growth. Basel and London, 5 September 2012

Media Release. Roche committed to innovation and growth. Basel and London, 5 September 2012 Media Release Basel and London, 5 September 2012 Roche committed to innovation and growth Personalised healthcare leadership and world-class pipeline presented at investor conference Industry-leading pipeline

More information

National Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007

National Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007 Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia

More information

Roche delivers good sales growth in the first nine months of 2016

Roche delivers good sales growth in the first nine months of 2016 Investor Update Basel, 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 Group sales increase 4% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division

More information

TRANSPARENCY COMMITTEE OPINION. 8 November 2006

TRANSPARENCY COMMITTEE OPINION. 8 November 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,

More information

Issue Date: 8 July Call for Independent Medical Education (IME) Notification: Roche Scientific Communications

Issue Date: 8 July Call for Independent Medical Education (IME) Notification: Roche Scientific Communications Call for Independent Medical Education (IME) Notification: Roche Scientific Communications Therapeutic Area and Disease: Hematology Lymphoma The Global Medical Affairs Hematology Team at Roche invites

More information

Learn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1

Learn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1 Learn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1 Expression of B-cell surface antigens drives several non-hodgkin s lymphomas (NHLs)

More information

Disclosures WOJCIECH JURCZAK

Disclosures WOJCIECH JURCZAK Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017

More information